X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC PHARMA with Sterling Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs STERLING BIOTECH - Comparison Results

STERLING BIOTECH 
   Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA STERLING BIOTECH ALEMBIC PHARMA/
STERLING BIOTECH
 
P/E (TTM) x 27.3 -0.4 - View Chart
P/BV x 5.5 0.0 39,178.4% View Chart
Dividend Yield % 0.6 0.0 -  

Financials

 ALEMBIC PHARMA   STERLING BIOTECH
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-18
STERLING BIOTECH
Dec-13
ALEMBIC PHARMA/
STERLING BIOTECH
5-Yr Chart
Click to enlarge
High Rs64511 6,143.8%   
Low Rs4703 13,817.6%   
Sales per share (Unadj.) Rs166.126.8 619.5%  
Earnings per share (Unadj.) Rs21.9-15.0 -146.4%  
Cash flow per share (Unadj.) Rs27.5-5.5 -503.3%  
Dividends per share (Unadj.) Rs4.000-  
Dividend yield (eoy) %0.70-  
Book value per share (Unadj.) Rs117.854.9 214.6%  
Shares outstanding (eoy) m188.52267.87 70.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.40.3 1,294.7%   
Avg P/E ratio x25.5-0.5 -5,478.5%  
P/CF ratio (eoy) x20.3-1.3 -1,593.8%  
Price / Book Value ratio x4.70.1 3,737.9%  
Dividend payout %18.30-   
Avg Mkt Cap Rs m105,0901,862 5,644.9%   
No. of employees `000NA1.4 0.0%   
Total wages/salary Rs m6,228547 1,139.0%   
Avg. sales/employee Rs ThNM5,303.3-  
Avg. wages/employee Rs ThNM403.8-  
Avg. net profit/employee Rs ThNM-2,959.0-  
INCOME DATA
Net Sales Rs m31,3087,181 436.0%  
Other income Rs m7043 165.0%   
Total revenues Rs m31,3787,223 434.4%   
Gross profit Rs m6,431947 679.2%  
Depreciation Rs m1,0552,543 41.5%   
Interest Rs m344,377 0.8%   
Profit before tax Rs m5,413-5,931 -91.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m-810-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,204-1,924 -62.5%   
Profit after tax Rs m4,128-4,007 -103.0%  
Gross profit margin %20.513.2 155.8%  
Effective tax rate %22.232.4 68.5%   
Net profit margin %13.2-55.8 -23.6%  
BALANCE SHEET DATA
Current assets Rs m18,24714,335 127.3%   
Current liabilities Rs m11,23549,809 22.6%   
Net working cap to sales %22.4-494.0 -4.5%  
Current ratio x1.60.3 564.3%  
Inventory Days Days86403 21.2%  
Debtors Days Days61171 36.0%  
Net fixed assets Rs m20,03555,432 36.1%   
Share capital Rs m377268 140.7%   
"Free" reserves Rs m21,82413,935 156.6%   
Net worth Rs m22,20114,701 151.0%   
Long term debt Rs m5,0009,478 52.8%   
Total assets Rs m39,41173,988 53.3%  
Interest coverage x160.2-0.4 -45,130.1%   
Debt to equity ratio x0.20.6 34.9%  
Sales to assets ratio x0.80.1 818.5%   
Return on assets %10.60.5 2,108.5%  
Return on equity %18.6-27.3 -68.2%  
Return on capital %19.7-6.4 -307.0%  
Exports to sales %46.425.9 179.2%   
Imports to sales %10.50.2 6,181.9%   
Exports (fob) Rs m14,5351,860 781.5%   
Imports (cif) Rs m3,28812 26,953.3%   
Fx inflow Rs m14,7221,860 791.6%   
Fx outflow Rs m7,02625 28,227.4%   
Net fx Rs m7,6961,835 419.4%   
CASH FLOW
From Operations Rs m3,1241,719 181.8%  
From Investments Rs m-8,844-3,148 280.9%  
From Financial Activity Rs m5,0261,426 352.5%  
Net Cashflow Rs m-693-3 20,391.2%  

Share Holding

Indian Promoters % 74.1 33.9 218.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.9 0.0 -  
FIIs % 9.1 9.9 91.9%  
ADR/GDR % 0.0 16.9 -  
Free float % 13.9 39.3 35.4%  
Shareholders   49,328 21,482 229.6%  
Pledged promoter(s) holding % 0.0 55.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   SUN PHARMA  DR. REDDYS LAB  GSK PHARMA  FULFORD INDIA  MERCK LTD  

Compare ALEMBIC PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

ALEMBIC PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 42.6% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, ALEMBIC PHARMA has posted a net profit of Rs 904 m (up 42.6% YoY). Sales on the other hand came in at Rs 9 bn (up 33.1% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 7.1% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 7.1% YoY). Sales on the other hand came in at Rs 9 bn (up 15.1% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Sep 21, 2018 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA 8-QTR ANALYSIS

COMPARE ALEMBIC PHARMA WITH

MARKET STATS